$338.45
14.794.57%
al cierre: -
$338.89
0.440.13%
After hour: 7:48 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Amgen Inc tiene un precio objetivo de consenso de $323.11 basado en las calificaciones de 31 analistas. El máximo es $405, emitido por Cantor Fitzgerald el octubre 22, 2024. El mínimo es $215, emitido por Baird el septiembre 25, 2024. Las 3 calificaciones de analistas más recientes fueron publicadas por Cantor Fitzgerald, Morgan Stanley y Wells Fargo el noviembre 6, 2025, noviembre 5, 2025 y noviembre 5, 2025, respectivamente. Con un precio objetivo promedio de $314.67 entre Cantor Fitzgerald, Morgan Stanley y Wells Fargo, hay una -7.15% downside implícita para Amgen Inc según estas calificaciones más recientes de analistas.
Firmas de analistas que realizan recomendaciones1
Cantor Fitzgerald
Morgan Stanley
Wells Fargo
B of A Securities
Piper Sandler
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Amgen
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
11/06/2025 | -7.05% | Cantor Fitzgerald | $305 → $315 | Maintains | Neutral | |||
11/05/2025 | -2.92% | Morgan Stanley | $333 → $329 | Maintains | Equal-Weight | |||
11/05/2025 | -11.48% | Wells Fargo | $280 → $300 | Maintains | Overweight | |||
09/26/2025 | -19.74% | B of A Securities | $261 → $272 | Maintains | Underperform | |||
09/03/2025 | — | Raymond James | — | Assumes | → Market Perform | |||
08/25/2025 | 0.92% | Piper Sandler | $328 → $342 | Maintains | Overweight | |||
08/06/2025 | -8.52% | Citigroup | $305 → $310 | Maintains | Neutral | |||
08/06/2025 | -1.74% | Morgan Stanley | $330 → $333 | Maintains | Equal-Weight | |||
08/06/2025 | -6.46% | UBS | $326 → $317 | Maintains | Neutral | |||
07/23/2025 | -22.98% | B of A Securities | $252 → $261 | Maintains | Underperform | |||
07/22/2025 | -10% | Citigroup | $300 → $305 | Maintains | Neutral | |||
07/21/2025 | -3.8% | UBS | $315 → $326 | Maintains | Neutral | |||
06/27/2025 | -3.21% | Piper Sandler | $328 → $328 | Reiterates | Overweight → Overweight | |||
06/24/2025 | -10% | Cantor Fitzgerald | $305 → $305 | Reiterates | Neutral → Neutral | |||
05/20/2025 | -15.02% | Guggenheim | → $288 | Assumes | → Neutral | |||
05/16/2025 | -3.21% | Piper Sandler | $329 → $328 | Maintains | Overweight | |||
05/07/2025 | -17.38% | Mizuho | $235 → $280 | Maintains | Neutral | |||
05/02/2025 | -7.05% | UBS | $319 → $315 | Maintains | Neutral | |||
05/02/2025 | -5.57% | RBC Capital | $324 → $320 | Maintains | Outperform | |||
04/14/2025 | -5.87% | UBS | $315 → $319 | Maintains | Neutral | |||
04/09/2025 | -2.62% | Morgan Stanley | $328 → $330 | Maintains | Equal-Weight | |||
03/05/2025 | -13.25% | B of A Securities | $275 → $294 | Maintains | Underperform | |||
02/10/2025 | -2.92% | Piper Sandler | $310 → $329 | Maintains | Overweight | |||
02/06/2025 | -18.85% | B of A Securities | $256 → $275 | Maintains | Underperform | |||
02/05/2025 | -3.21% | Morgan Stanley | $322 → $328 | Maintains | Equal-Weight | |||
01/29/2025 | 2.1% | BMO Capital | $362 → $346 | Maintains | Outperform | |||
01/28/2025 | -12.95% | Citigroup | $310 → $295 | Maintains | Neutral | |||
01/24/2025 | -4.39% | RBC Capital | $324 → $324 | Reiterates | Outperform → Outperform | |||
01/10/2025 | -17.38% | Wells Fargo | $335 → $280 | Maintains | Equal-Weight | |||
01/08/2025 | -12.07% | Truist Securities | $333 → $298 | Maintains | Hold | |||
01/02/2025 | -8.52% | Piper Sandler | $344 → $310 | Maintains | Overweight | |||
12/10/2024 | -24.46% | B of A Securities | → $256 | Reinstates | → Underperform | |||
11/27/2024 | -2.62% | RBC Capital | $360 → $330 | Maintains | Outperform | |||
11/15/2024 | — | Wolfe Research | — | Initiates | → Peer Perform | |||
11/14/2024 | -1.15% | Citigroup | → $335 | Initiates | → Neutral | |||
11/12/2024 | 12.13% | Jefferies | $380 → $380 | Maintains | Buy | |||
10/31/2024 | -3.8% | UBS | $335 → $326 | Maintains | Neutral | |||
10/22/2024 | 19.51% | Cantor Fitzgerald | $405 → $405 | Reiterates | Overweight → Overweight | |||
10/21/2024 | 13.02% | TD Cowen | $381 → $383 | Maintains | Buy | |||
10/17/2024 | 12.13% | Bernstein | → $380 | Initiates | → Outperform | |||
10/14/2024 | -1.74% | Truist Securities | $320 → $333 | Downgrade | Buy → Hold | |||
10/07/2024 | -7.05% | Barclays | $300 → $315 | Maintains | Equal-Weight | |||
09/27/2024 | 19.51% | Cantor Fitzgerald | → $405 | Initiates | → Overweight | |||
09/26/2024 | 6.82% | RBC Capital | $362 → $362 | Reiterates | Outperform → Outperform | |||
09/25/2024 | -36.56% | Baird | $215 → $215 | Reiterates | Underperform → Underperform | |||
08/07/2024 | 12.43% | TD Cowen | $360 → $381 | Maintains | Buy | |||
08/07/2024 | 12.13% | Oppenheimer | $380 → $380 | Maintains | Outperform | |||
08/07/2024 | -10% | Deutsche Bank | $310 → $305 | Reiterates | Hold → Hold | |||
08/07/2024 | -2.62% | B of A Securities | $325 → $330 | Maintains | Neutral | |||
08/07/2024 | 6.82% | RBC Capital | $332 → $362 | Maintains | Outperform | |||
08/07/2024 | -1.15% | Wells Fargo | $320 → $335 | Downgrade | Overweight → Equal-Weight | |||
07/12/2024 | -0.56% | UBS | $307 → $337 | Maintains | Neutral | |||
07/11/2024 | -10.59% | Morgan Stanley | $310 → $303 | Maintains | Equal-Weight | |||
06/27/2024 | 0.33% | Argus Research | $300 → $340 | Maintains | Buy | |||
06/14/2024 | -2.03% | RBC Capital | $328 → $332 | Maintains | Outperform | |||
05/09/2024 | -30.66% | Mizuho | $223 → $235 | Maintains | Neutral | |||
05/03/2024 | -3.21% | RBC Capital | $332 → $328 | Maintains | Outperform | |||
05/03/2024 | -8.52% | Morgan Stanley | $271 → $310 | Maintains | Equal-Weight | |||
05/03/2024 | -9.41% | UBS | $284 → $307 | Maintains | Neutral | |||
05/03/2024 | — | William Blair | — | Upgrade | Market Perform → Outperform | |||
05/03/2024 | 4.75% | BMO Capital | $336 → $355 | Maintains | Outperform | |||
05/03/2024 | -11.48% | Barclays | $230 → $300 | Upgrade | Underweight → Equal-Weight | |||
04/17/2024 | -16.2% | UBS | $314 → $284 | Maintains | Neutral | |||
04/17/2024 | 6.23% | TD Cowen | $370 → $360 | Maintains | Buy | |||
04/12/2024 | -5.57% | Truist Securities | $320 → $320 | Reiterates | Buy → Buy | |||
04/09/2024 | -20.03% | Morgan Stanley | $278 → $271 | Maintains | Equal-Weight | |||
04/03/2024 | -2.92% | RBC Capital | $329 → $329 | Reiterates | Outperform → Outperform | |||
03/28/2024 | — | Raymond James | — | Reinstates | → Market Perform | |||
02/08/2024 | 3.28% | Goldman Sachs | $313 → $350 | Maintains | Buy | |||
02/07/2024 | -17.97% | Morgan Stanley | $281 → $278 | Maintains | Equal-Weight | |||
02/07/2024 | -2.92% | RBC Capital | $303 → $329 | Maintains | Outperform | |||
02/07/2024 | 3.28% | Goldman Sachs | $313 → $350 | Maintains | Buy | |||
02/01/2024 | 3.28% | Oppenheimer | $350 → $350 | Reiterates | Outperform → Outperform | |||
01/29/2024 | -7.34% | UBS | $315 → $314 | Maintains | Neutral | |||
12/21/2023 | -5.57% | Daiwa Capital | → $320 | Upgrade | Neutral → Buy | |||
12/19/2023 | -3.8% | BMO Capital | $286 → $326 | Upgrade | Market Perform → Outperform | |||
12/12/2023 | -11.48% | RBC Capital | $256 → $300 | Upgrade | Sector Perform → Outperform | |||
11/29/2023 | -5.57% | Truist Securities | → $320 | Reiterates | Buy → Buy | |||
11/09/2023 | -29.18% | Deutsche Bank | → $240 | Initiates | → Hold | |||
11/02/2023 | -24.46% | RBC Capital | $253 → $256 | Maintains | Sector Perform | |||
11/02/2023 | -5.57% | Truist Securities | → $320 | Upgrade | Hold → Buy | |||
11/02/2023 | -20.92% | UBS | $272 → $268 | Maintains | Neutral | |||
11/01/2023 | -24.46% | RBC Capital | $253 → $256 | Maintains | Sector Perform | |||
11/01/2023 | -14.13% | Morgan Stanley | $300 → $291 | Maintains | Equal-Weight | |||
10/25/2023 | -8.52% | Oppenheimer | $300 → $310 | Maintains | Outperform | |||
10/20/2023 | -11.48% | Oppenheimer | $290 → $300 | Maintains | Outperform | |||
10/20/2023 | -20.33% | JP Morgan | → $270 | Reinstates | Neutral → Neutral | |||
10/17/2023 | -8.52% | Argus Research | $280 → $310 | Maintains | Buy | |||
10/17/2023 | -11.48% | Morgan Stanley | → $300 | Reinstates | → Equal-Weight | |||
10/12/2023 | -5.57% | Wells Fargo | $265 → $320 | Maintains | Overweight | |||
10/12/2023 | -8.52% | Jefferies | $310 → $310 | Reiterates | Buy → Buy | |||
10/11/2023 | -6.16% | Leerink Partners | $267 → $318 | Upgrade | Market Perform → Outperform | |||
10/11/2023 | -14.43% | B of A Securities | → $290 | Reinstates | → Neutral | |||
10/09/2023 | -14.43% | Oppenheimer | $280 → $290 | Maintains | Outperform | |||
09/18/2023 | -17.38% | Argus Research | $260 → $280 | Maintains | Buy | |||
09/06/2023 | -5.57% | HSBC | → $320 | Initiates | → Buy | |||
09/05/2023 | -23.28% | Truist Securities | → $260 | Reiterates | Hold → Hold | |||
08/14/2023 | -8.52% | Jefferies | $275 → $310 | Maintains | Buy | |||
08/14/2023 | -34.2% | Mizuho | $214 → $223 | Maintains | Neutral | |||
08/04/2023 | -25.34% | RBC Capital | $250 → $253 | Maintains | Sector Perform |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Amgen (AMGN)?
El último precio objetivo de Amgen (NASDAQ:AMGN) fue comunicado por Cantor Fitzgerald el noviembre 6, 2025. La firma de analistas fijó un precio objetivo para $315.00 que espera AMGN a fall dentro de 12 meses (un posible -7.05% downside). 35 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Amgen (AMGN)?
La última calificación de analistas para Amgen (NASDAQ:AMGN) fue proporcionada por Cantor Fitzgerald, y Amgen mantuvo su neutral calificación.
¿Cuándo se produjo la última revisión al alza de Amgen (AMGN)?
La última revisión al alza de Amgen Inc se produjo en mayo 3, 2024, cuando William Blair elevó su precio objetivo a N/A. William Blair anteriormente tenía a market perform para Amgen Inc.
¿Cuándo fue la última revisión a la baja de Amgen (AMGN)?
La última revisión a la baja de Amgen Inc se produjo en octubre 14, 2024, cuando Truist Securities cambió su precio objetivo de $320 a $333 para Amgen Inc.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Amgen (AMGN)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Amgen, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Amgen se registró el noviembre 6, 2025, por lo que la próxima calificación estará disponible en torno al noviembre 6, 2026.
¿Es correcta la calificación de los analistas sobre Amgen (AMGN)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Amgen (AMGN) fue un mantuvo con un precio objetivo de $305.00 a $315.00. El precio actual al que cotiza Amgen (AMGN) es de $338.89, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.